Development of a membrane-targeted complement inhibitor for clinical use

Author： Dodd I.   Oldroyd R.G.   Powell S.   Affleck L.J.   Bamber L.   Gallagher S.   Rowling P.J.E.   Ragnauth C.   Smith G.P.   Pratt J.R.   Sacks S.H.   Linton S.M.   Morgan B.P.   Smith R.A.G.  

Publisher： Elsevier

ISSN： 0162-3109

Source： Immunopharmacology, Vol.49, Iss.1, 2000-08, pp. : 63-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Synthetic Membrane-Targeted Antibiotics

By  

Current Medicinal Chemistry, Vol. 17, Iss. 21, 2010-07 ,pp. : 2292-2300

Bentham Science Publishers

Access to resources Recommend Favorite

Membrane-Targeted Self-Assembling Cyclic Peptide Nanotubes

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 23, 2014-12 ,pp. : 2647-2661

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

By  

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 922-931

Bentham Science Publishers

Access to resources Recommend Favorite

Development of gonadotrophins for clinical use

By Lunenfeld Bruno  

Reproductive BioMedicine Online, Vol. 4, Iss. 1, 2002-03 ,pp. : 11-17

Reproductive Healthcare Ltd

Access to resources Recommend Favorite